Damla GÜNENÇ EŞİM
Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalı
Research areas: Health Sciences, Medicine, Life Sciences, Animal Biology, Histology and Embryology, Neuroanatomy, Neurobiology
Publications
- A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications (2025)
- RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025)
- Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics (2025)
- Prognostic Value of Blood-Based Inflammatory Markers in Cancer Patients Receiving Immune Checkpoint Inhibitors (2025)
- Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma. (2024)
- Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune checkpoint inhibitor (ICI) regimens and circulating biomarkers (2024)
- Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN) (2024)
- Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature (2024)
- Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune checkpoint inhibitor (ICI) regimens and circulating biomarkers. (2024)
- Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma (2024)
- Treatment outcomes for patients with Ga68-PSMA-PET prostate cancer (PC) with or without conventional imaging correlates (2024)
- Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report (2024)
- PRIMARY TUMOR RESPONSE TO PRE-OPERATIVE IMMUNE CHECKPOINT INHIBITION IN LOCALIZED CLEAR CELL RENAL CELL CARCINOMA (2023)
- Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs (2023)
- Engineering and evaluation of a novel circulating tumor cell capture assay for urothelial carcinoma (2023)
- Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study (2022)
- Immunotherapy-induced granulomatous reaction in patients with melanoma (2022)
- Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study (2022)
- PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment (2022)
- Immunotherapy-induced granulomatous reaction in patients with melanoma (2022)
- Neoadjuvan tedavide Pertuzumab alan meme kanseri hastalarının genel özellikleri (2021)
- Denovo metastatik pankreas kanserinde FOLFİRİNOX tedavisi sırasında gelişen hipoalbumineminin sağkalım üzerine etkisinin değerlendirilmesi (2021)
- Demonstration of PTZ-induced convulsive-reducing effect of butamirate citrate (2018)
- Demonstration of PTZ-Induced Convulsive-Reducing Effect of Butamirate Citrate (2018)
- Antifibrotic effect of lactulose on a methotrexate-induced liver injury model (2017)
- Böbrek naklinde terapötik plazmaferez kullanımı (2017)
- Böbrek nakillerinde sağkalımı etkileyen faktörler (2017)
- Cancer immunotherapy (2017)
- CLINICAL EFFICACY OF IMATINIB MESYLATE HOMOLOG DRUGS IN CHRONICMYELOID LEUKEMIA PATIENTS (2016)
- A Case of Colon Adenocarcinoma in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib (2015)
- NON HODGKİN LENFOMA TANILI HASTALARDA OTOLOG KÖK HÜCRE NAKLİ İÇİN HAZIRLAMA REJİMİ OLARAK TECAM THIOTEPA ETOPOSIDE ARA C CYCLOPHOSPHAMIDE MELPHALAN RETROSPEKTİF TEK MERKEZ DENEYİMİ (2015)
- MONOSOMY 16 IS A NEW PROGNOSTİC FACTOR FOR CLL (2015)
- MEDISATİNAL T LYMPHOBLASTIC LYMPHOMA RELAPSED WITH HYPEREOSINOPHILIA (2015)